Half-Year 2022 Financial and Clinical Trials Update
Ipatasertib (RG7440, GDC-0068)
Highly selective small molecule inhibitor of Akt
Indication
Phase/study
# of patients
▪ ARM A: Ipatasertib plus abiraterone
Design
☐
▪ ARM B: Placebo plus abiraterone
1L castration-resistant prostate cancer (CRPC)
Phase III
IPATential150
N=1,100
Primary endpoint
Status
"
rPFS in patients with PTEN loss tumors and overall population
FPI Q2 2017
Recruitment completed Q1 2019
▪ Study met co-primary endpoint in rPFS in patients with PTEN loss tumors Q2 2020
Data presented at ESMO 2020 and interim OS at ASCO 2022
■ Published in Lancet 2021; 398:131-142
CT Identifier
NCT03072238
Akt-Protein Kinase B; PTEN=Phosphatase and Tensin homolog; rPFS-Radiographic progression-free survival; ESMO-European Society for Medical Oncology
126
Roche
OncologyView entire presentation